Radiation Oncology

Non-Hodgkin Lymphoma

Questions discussed in this category

Does the choice of radiation modality (3D, IMRT/VMAT, protons) impact the effectiveness of the reduced dose of 20 Gy in DLBCL?

Would you prefer certain modalities if using the lower dose? This question is part of our collaboration with ASTRO 2025 to highlight impactfu...

1 Answer available

What criteria would you consider to select patients for 20 Gy consolidative RT in DLBCL/HGBL?

Should the reduced dose be adopted for all, or would you reserve this approach for specific patient subgroups? This question is part of our c...

1 Answer available

How do you incorporate radiation therapy in patients undergoing CAR T-cell therapy for DLBCL?

2 Answers available

Would you recommend RT for DLBCL of a pre-isthmus node incidentally found during thyroidectomy for papillary thyroid cancer?

If the patient has received RCHOPx3 and the post treatment PET is negative, what would your management be?

1 Answer available

Papers discussed in this category

Blood,

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

International journal of radiation oncology, biology, physics, 2019-12-01

Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.

The Lancet. Oncology, 2019-01

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Molecular therapy : the journal of the American Society of Gene Therapy, 2018-11-07

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

Cancer immunology research, 2019-07

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Br J Haematol, 2020 Mar 5

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.

Lancet, 2020 Sep 01

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Blood Adv,

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.

Int J Radiat Oncol Biol Phys, 2020 May 22

Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.

The New England journal of medicine, 2017-12-28

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Radiother Oncol, 2021 Dec 7

Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?

Int J Radiat Oncol Biol Phys, 2021 Dec 1

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.

Int J Radiat Oncol Biol Phys, 2022 Dec 20

Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.

Transplant Cell Ther, 2022 Dec 30

Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.

Blood advances, 2020 Jul 28

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26

Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma.

Blood advances, 2020 Nov 24

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Haematologica, 2023 Jun 15

Consolidative radiotherapy for residual FDG activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma.

International journal of radiation oncology, biology, physics, 2025 Feb 22

Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma.

Radiation Oncology

Non-Hodgkin Lymphoma

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology